Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
February 18, 2021– Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared…Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
February 17, 2021– Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery…Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25
February 11, 2021NEW YORK, February 11, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. to Participate in Investor Conferences in January
January 5, 2021– Management Provides Update on Timing of Data for IMU-838 in Primary Sclerosing Cholangitis – NEW YORK, January 5, 2021 – Immunic,…